A. Mohammed F.H. and L.R. Roberts discussed the drawbacks of AFP and why the AASLD is not in favor of endorsing AFP as a standalone biomarker in their guidelines, partly based on still missing evidence supporting its high sensitivity and specificity as an effective surveillance and diagnostic tool for HCC [40]. The gene discussed is AFP; the disease is hepatocellular carcinoma.